FDA approves ABRAXANE for first-line treatment of advanced NSCLC Celgene Corporation announced the FDA has approved ABRAXANE for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. Additional regulatory submissions have been filed in Japan, Australia and New Zealand with anticipated decisions in 2013. This approval marks the second indication for ABRAXANE in the United States. In the United States, ABRAXANE was first approved in 2005 for the treatment of metastatic breast cancer after failure of combination chemotherapy.
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.
Subscribe for More Information